BIOA · Insider Trading
BioAge Labs, Inc. Common Stock
Every open-market purchase and sale reported by BIOA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Shane Barton | Principal Accounting Officer | MIXED | −2,632 | −$1.18M |
| 2026-06-12 | Rekha Hemrajani | Director | A | +22,000 deriv. | — |
| 2026-06-12 | Michael H. Davidson | Director | A | +22,000 deriv. | — |
| 2026-06-12 | James Healy | Director | A | +22,000 deriv. | — |
| 2026-06-12 | Vijay Satyanand Pande | Director | A | +22,000 deriv. | — |
| 2026-06-12 | Jean Pierre Garnier | Director | A | +22,000 deriv. | — |
| 2026-06-12 | Patrick G Enright | Director | A | +22,000 deriv. | — |
| 2026-04-24 | Dov A Md Goldstein | Chief Financial Officer | M | +3,542 | +$15.51K |
| 2026-04-03 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$112.51K |
| 2026-03-03 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$115.42K |
| 2026-03-03 | Dov A Md Goldstein | Chief Financial Officer | M | +3,542 | +$15.51K |
| 2026-02-19 | Paul D Rubin | Chief Medical Officer | A | +110,000 deriv. | — |
| 2026-02-19 | Eric Morgen | Chief Operating Officer | A | +122,500 deriv. | — |
| 2026-02-19 | Dov A Md Goldstein | Chief Financial Officer | A | +110,000 deriv. | — |
| 2026-02-19 | Shane Barton | Principal Accounting Officer | A | +45,000 deriv. | — |
| 2026-02-19 | Kristen Fortney | Chief Executive Officer | A | +330,000 deriv. | — |
| 2026-02-03 | Dov A Md Goldstein | Chief Financial Officer | M | +3,541 | +$15.51K |
| 2026-02-03 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$103.90K |
| 2026-01-21 | Dov A Md Goldstein | Chief Financial Officer | M | +3,542 | +$15.51K |
| 2026-01-15 | Kristen Fortney | Chief Executive Officer | Sell | −233,107 | −$4.22M |
| 2026-01-15 | Dov A Md Goldstein | Chief Financial Officer | MIXED | — | −$305.30K |
| 2026-01-06 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$60.02K |
| 2025-12-11 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$97.74K |
| 2025-12-05 | Paul D Rubin | Chief Medical Officer | MIXED | — | −$418.74K |
| 2025-08-11 | Vijay Satyanand Pande | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Michael H. Davidson | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Patrick G Enright | Director | A | +22,000 deriv. | — |
| 2025-06-09 | James Healy | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Jean Pierre Garnier | Director | A | +22,000 deriv. | — |
| 2025-06-09 | Rekha Hemrajani | Director | A | +22,000 deriv. | — |
| 2025-03-10 | Shane Barton | Principal Accounting Officer | Buy | +2,632 | +$47.38K |
| 2025-03-10 | Rekha Hemrajani | Director | Buy | +3,000 | +$54.00K |
| 2025-02-25 | Eric Morgen | Chief Operating Officer | A | +25,000 deriv. | — |
| 2025-02-20 | Eric Morgen | Chief Operating Officer | A | +200,000 deriv. | — |
| 2025-02-20 | Kristen Fortney | Chief Executive Officer | A | +530,000 deriv. | — |
| 2025-02-20 | Shane Barton | Principal Accounting Officer | A | +90,000 deriv. | — |
| 2025-02-20 | Dov A Md Goldstein | Chief Financial Officer | A | +170,000 deriv. | — |
| 2025-02-20 | Paul D Rubin | Chief Medical Officer | A | +200,000 deriv. | — |
| 2024-12-20 | Shane Barton | Principal Accounting Officer | A | +40,000 deriv. | — |
| 2024-10-03 | Vijay Satyanand Pande | Director | Buy | +219,195 | +$4.33M |
| 2024-10-01 | Cormorant Private Healthcare Fund IV LP | — | MIXED | +6,518,116 | +$32.40M |
| 2024-09-27 | Kristen Fortney | Chief Executive Officer | A | +1,132,871 deriv. | — |
| 2024-09-27 | Patrick G Enright | Director | MIXED | +1,710,589 | +$7.20M |
| 2024-09-27 | Michael H. Davidson | Director | A | +48,986 deriv. | — |
| 2024-09-27 | Eric Morgen | Chief Operating Officer | A | +276,523 deriv. | — |
| 2024-09-27 | Jean Pierre Garnier | Director | A | +156,609 deriv. | — |
| 2024-09-27 | Rekha Hemrajani | Director | A | +43,497 deriv. | — |
| 2024-09-27 | Vijay Satyanand Pande | Director | MIXED | +3,013,975 | +$16.20M |
| 2024-09-27 | James Healy | Director | MIXED | +2,304,901 | +$12.00M |
| 2017-12-04 | Kenneth W. Wall | Director | Buy | +40,000 | +$17.20K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James Healy | Director | 2,227,124 | $11.11M |
| Patrick G Enright | Director | 1,310,589 | $6.54M |
| Vijay Satyanand Pande | Director | 1,093,889 | $5.46M |
| Kristen Fortney | Chief Executive Officer | 976,949 | $4.87M |
| Dov A Md Goldstein | Chief Financial Officer | 36,575 | $182.51K |
| Shane Barton | Principal Accounting Officer | 11,933 | $59.55K |
| Paul D Rubin | Chief Medical Officer | 5,437 | $27.13K |
| Rekha Hemrajani | Director | 3,000 | $14.97K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIOA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.